Thyroid cancer
Jump to navigation
Jump to search
Section editor | |
---|---|
Unfilled If you are interested in this role, please contact us at [email protected]. |
Note: most thyroid cancer regimens can be found on dedicated pages:
- Histology-specific:
- Biomarker-specific:
Last updated on 2024-07-23: 3 regimens on this page
3 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ESMO
NCCN
- NCCN Guidelines - Thyroid Carcinoma
- 2015: Haddad et al. Anaplastic Thyroid Carcinoma, Version 2.2015 PubMed
- 2014: Tuttle et al. Thyroid Carcinoma, Version 2.2014 PubMed
- 2010: Tuttle et al. Thyroid carcinoma. PubMed
- 2007: Sherman et al. Thyroid carcinoma. PubMed
- 2005: Sherman et al. Thyroid carcinoma. PubMed
Advanced or metastatic disease
Axitinib monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Cohen et al. 2008 (A4061014) | Not reported | Phase 2 |
References
- A4061014: Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10;26(29):4708-13. Epub 2008 Jun 9. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00094055
- Update: Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014 Dec;74(6):1261-70. Epub 2014 Oct 15. link to original article link to PMC article PubMed
Doxorubicin monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Gottlieb et al. 1974 | 1971-01 to 1973-06 | Non-randomized |
Note: This is of historic interest.
References
- Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with adriamycin: experience with 30 patients. N Engl J Med. 1974 Jan 24;290(4):193-7. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Sorafenib monotherapy
Regimen
Study | Dates of enrollment | Evidence | Efficacy |
---|---|---|---|
Gupta-Abramson et al. 2008 | 2006-02-28 to 2007-09-13 | Phase 2 | ORR: 23% (95% CI, 10-42) |
References
- Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008 Oct 10;26(29):4714-9. Epub 2008 Jun 9. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed